Ilumya (tildrakizumab-asmn) Letter of Medical Necessity
Ilumya (tildrakizumab) is an IL-23 inhibitor for plaque psoriasis given in the office every 12 weeks, so it is often reviewed on the medical benefit. Denials usually turn on missing severity scores, missing step therapy, or a preferred IL-23 agent. A focused Letter of Medical Necessity addresses each.
FDA-Approved Indications
- ● moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Why Ilumya Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. BSA, PASI, or special-site involvement not documented
- 2. Phototherapy or conventional systemic agent not tried first
- 3. Preferred biologic (Skyrizi, Tremfya, or a biosimilar) on formulary
- 4. Billed under the wrong benefit — Ilumya is administered by a healthcare professional
- 5. TB screening not on file
What to Include in a Ilumya Letter of Medical Necessity
Document BSA, PASI, and any special-site involvement (scalp, nails, palms, genitals), plus prior topical, phototherapy, and systemic agents with dates and outcomes. Include TB screening, explain why office administration every 12 weeks supports adherence for this patient, and address any formulary-preferred IL-23 agent.
Key clinical evidence to cite:
- ✓ reSURFACE 1 and 2 Phase 3 trials — PASI 75 superiority vs placebo and etanercept
- ✓ Five-year extension data showing durable response and a stable safety profile
- ✓ Every-12-week maintenance dosing given in the office
Relevant guidelines:
- 📖 AAD-NPF 2019 Psoriasis Guidelines (Biologics)
- 📖 AAD-NPF 2020 Systemic Non-Biologic Therapy Guidelines
Ilumya Prior Authorization Criteria
Standard criteria across major US payers for Ilumya. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Ilumya
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Ilumya Prior Authorization FAQ
Why was my Ilumya prior authorization denied?
The most common denial reasons for Ilumya are: BSA, PASI, or special-site involvement not documented; Phototherapy or conventional systemic agent not tried first; Preferred biologic (Skyrizi, Tremfya, or a biosimilar) on formulary; Billed under the wrong benefit — Ilumya is administered by a healthcare professional; TB screening not on file.
What should a Ilumya Letter of Medical Necessity include?
Document BSA, PASI, and any special-site involvement (scalp, nails, palms, genitals), plus prior topical, phototherapy, and systemic agents with dates and outcomes. Include TB screening, explain why office administration every 12 weeks supports adherence for this patient, and address any formulary-preferred IL-23 agent.
Which payers cover Ilumya?
Ilumya is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part B, though formulary tier and prior authorization criteria vary.